Timing of Anticoagulant Administration During Radial Access Percutaneous Coronary Intervention: the HERA-PCI Study (Heparin Early for Radial Access Percutaneous Coronary Intervention)

Launched by UNIVERSITY HOSPITAL, STRASBOURG, FRANCE · Mar 19, 2025

Keywords

ClinConnect Summary

The HERA-PCI Study is a clinical trial that is investigating the best timing for administering heparin, a blood thinner, during a specific heart procedure called percutaneous coronary intervention (PCI) using the radial artery in the wrist. While using the wrist instead of the groin for this procedure is generally safer and has a lower risk of bleeding, one of the main problems is that it can cause the radial artery to become blocked in some patients. The researchers believe that giving heparin before inserting the special tube (sheath) used in the procedure might help reduce the chances of this blockage compared to giving it afterward.

To participate in this study, you need to be at least 18 years old and scheduled for a PCI using the radial artery. You also need to understand the purpose of the study and agree to take part by signing a consent form. However, if you have certain conditions, such as a history of serious reactions to heparin or are currently on other blood-thinning medications, you may not be eligible. This trial is still in the planning stages and is not yet recruiting participants, but it aims to improve care for patients undergoing heart procedures.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients having 18 years old or older, regardless of gender, undergoing percutaneous radial coronary intervention
• • Subject affiliated to a social protection health insurance
• • Subject able to understand the objectives and risks of the research and to provide dated and signed consent
• • Subject who has been informed of the results of the preliminary medical examination
• Exclusion Criteria:
• • Contraindication to the use of heparin (history of heparin-induced thrombocytopenia)
• • Very high bleeding risk defined by recent bleeding (\<6 months) of type 3 of the BARC classification
• • Subject in an exclusion period (determined by a previous or ongoing study)
• • Inability to give the subject enlightened information (subject in an emergency situation, difficulties in understanding the subject, etc.)
• • Subject under safeguard of justice
• • Subject under guardianship or curatorship
• • Pregnancy
• • Breastfeeding
• • Patient on anticoagulant treatment: anti-vitamin K, direct oral anticoagulants (DOACs).